PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
-
PROTACs Related Products (1375)
Related Products (1375)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
FAK PROTAC B5
0 ImagesCat. No.: HY-143458CAS No.: 2471525-44-5FAK PROTAC B5 is a FAK PROTAC degrader with an IC50 of 14.9 nM. FAK PROTAC B5 induces FAK degradation via the ubiquitin-proteasome pathway by simultaneously binding to FAK and the CRBN E3 ligase. FAK PROTAC B5 inhibits the proliferation, migration and invasion of cancer cells. FAK PROTAC B5 can be used for the research of non-small cell lung cancer.
-
ZS3-046
0 ImagesCat. No.: HY-176457CAS No.: 3087879-97-5ZS3-046 is a potent TAF1 PROTAC degrader with a DC50 < 10 nM. ZS3-046 recruits the CRBN E3 ubiquitin ligase, promotes polyubiquitination and proteasomal degradation of TAF1, thereby activating p53 and downregulating c-Myc, and ultimately induces apoptosis of tumor cells. ZS3-046 can be used in research related to acute myeloid leukemia.
-
DN1679
0 ImagesCat. No.: HY-181035DN1679 is a potent, selective and orally active CRBN-dependent CDK12/13 PROTAC dual degrader. DN1679 shows DC50 of 8.8/9.8 nM (MDA-MB-231), 5.1/6.4 nM (MDA-MB-157) and 17.2/15.8 nM (MDA-MB-468) for CDK12/13. DN1679 can downregulate DNA damage response gene mRNA levels, such as ATM, ATR, BRCA1 and RAD51. DN1679 demonstrates a potent synergistic anti-tumor effect companied with Olaparib (HY-10162). DN1679 can be used for research of triple-negative breast cance.
-
PROTAC ITK degrader 1
0 ImagesCat. No.: HY-149917PROTAC ITK degrader 1 is a highly selective degrader of interleukin-2-inducible T-cell kinase (ITK; DC50=3.6 nM in vivo in mice), with good plasma exposure levels. PROTAC ITK degrader 1 induces rapid, and prolonged ITK degradation and suppresses IL-2 secretion (EC50=35.2 nM, Jurkat cells) stimulated by anti-CD3 antibodyin vivo.
-
MD-4251
0 ImagesCat. No.: HY-174458MD-4251 is an orally active MDM2 PROTAC degrader with a DC50 of 0.2 nM in RS4;11 cells. MD-4251 induces cereblon-dependent depletion and degradation of MDM2 protein, elevates p53 protein levels and activates p53. MD-4251 inhibits the proliferation of wild-type p53 acute leukemia cells, induces complete and durable tumor regression in xenograft models, and upregulates the protein levels of DSC1, NBEA and CASP14. MD-4251 can be used in studies related to acute leukemia.
-
SMD-6346
0 ImagesCat. No.: HY-184673CAS No.: 3086248-19-0SMD-6346 is an orally active SMARCA2 PROTAC degrader with a DC50 of 3.3 nM. SMD-6346 induces SMARCA2 degradation and exhibits extremely low activity against SMARCA4. SMD-6346 inhibits the growth of SMARCA4-deficient cancer cells and suppresses tumor growth in mouse xenograft models. SMD-6346 can be used for the research of non-small cell lung cancer.
-
LC-1-40
0 ImagesCat. No.: HY-158062Purity: 99.65%LC-1-40 is a selective NUDT1 PROTAC degrader with a DC50 of 0.97 nM. LC-1-40 recruits NUDT1 to the CRBN E3 ubiquitin ligase complex and mediates its degradation via a proteasome-dependent pathway. LC-1-40 induces increased nucleotide damage and Apoptosis in tumors. LC-1-40 can be used in studies related to Mycn-amplified neuroblastoma.
-
MS2133
0 ImagesCat. No.: HY-173422MS2133 is a VHL-recruiting DOT1L PROTAC degrader. MS2133 possesses antiproliferative activity with a human DOT1L IC50 of 4.6 nM, forms a ternary complex with DOT1L and VHL E3 ligase to drive DOT1L ubiquitination and subsequent proteasomal degradation without affecting DOT1L mRNA transcription, inhibits the proliferation of mixed lineage leukemia-rearranged leukemia cells and downregulates H3K79Me2, restrains proliferation of both tumor and normal cells but lacks cytotoxicity against normal cells, and can be used for the research of mixed lineage leukemia-rearranged leukemia.
-
PROTAC ERα Y537S degrader-1
0 ImagesCat. No.: HY-145071CAS No.: 2667598-05-0
-
PROTAC KDM4 degrader-1
0 ImagesPROTAC KDM4 degrader-1 is a KDM4 PROTAC degrader that degrades KDM4A-C with DC50 values of 37.53, 39.93, and 49.41 nM, respectively, while sparing KDM4D. PROTAC KDM4 degrader-1 induces cell cycle arrest, apoptosis and antiproliferative activity in esophageal cancer cells. PROTAC KDM4 degrader-1 can be used for the research of esophageal cancer.
-
PROTAC BRD9 Degrader-5
0 ImagesCat. No.: HY-145947CAS No.: 2704616-86-2PROTAC BRD9 Degrader-5 is a BRD9 PROTAC degrader. PROTAC BRD9 Degrader-5 is used in research on acute myeloid leukemia, rhabdoid tumor, synovial sarcoma, and multiple myeloma.
-
LO-4-25
0 ImagesCat. No.: HY-176067LO-4-25 is a CUL4DCAF16 based covalent PROTAC-like degrader. LO-4-25 induces degradation of the androgen receptor (AR) and androgen receptor truncation variant AR-V7. LO-4-25 covalently targets cysteine residues on CUL4DCAF16 to mediate degradation of neo-substrates. LO-4-25 triggers proteasome-dependent degradation of target proteins via CUL4DCAF16-mediated ubiquitination. LO-4-25 can be used for the research of androgen-independent prostate cancer.
-
DD205-291
0 ImagesCat. No.: HY-168282CAS No.: 3047066-15-6DD205-291 is a selective, orally active HPK1 PROTAC degrader with a DC50 of 8.8 nM. By inducing complete degradation of HPK1 protein, DD205-291 simultaneously blocks both its kinase-dependent functions and non-kinase scaffold functions. DD205-291 inhibits the phosphorylation of SLP-76 with an EC50 of 22.98 nM. DD205-291 induces the production of IL-2 and IFN-γ with EC50 values of 34.68 nM and 32.6 nM, respectively. Combined with anti-PD1 in mouse models, DD205-291 exerts tumor-suppressive effects with favorable safety profiles. DD205-291 can be used in colon cancer-related research.
-
MS98
0 ImagesCat. No.: HY-145281CAS No.: 2376137-31-2MS98 is a AKT PROTAC degrader with a DC50 of 78 nM in BT474 cells. MS98 binds to purified AKT1, AKT2 and AKT3 isoforms with Kd values of 4 nM, 140 nM and 8 nM, respectively. MS98 recruits the VHL E3 ligase to induce polyubiquitination and proteasomal degradation of AKT. MS98 inhibits downstream signal transduction of the PI3K/AKT/m-TOR pathway. MS98 suppresses cancer cell proliferation. MS98 can be used for the research of prostate cancer and breast cancer.
-
DFCI-002-06
0 ImagesCat. No.: HY-181050CAS No.: 3092208-36-8DFCI-002-06 is an orally active dual-target HCK/BTK PROTAC degrader with DC₅₀ values for HCK and BTK of 1.3 and 4.5 nM respectively. DFCI-002-06 retains higher anti-tumor activity than the HCK/BTK dual-target inhibitor (HY-15805), inducing apoptosis in cancer cells. DFCI-002-06 can be used for the study of MYD88 mutant B-cell malignancies.
-
KG-FP-003
0 ImagesCat. No.: HY-186117CAS No.: 3066008-42-9KG-FP-003 is a highly potent, selective, and durable TEAD PROTAC degrader (TEAD1 DC50 = 6 ± 4 nM, TEAD2 DC50 = 68 ± 15 nM, TEAD3 DC50 = 12 ± 5 nM, TEAD4 DC50 = 7 ± 5 nM). KG-FP-003 promotes ubiquitination and degradation of TEAD. KG-FP-003 exhibits anticancer activity against mesothelioma and ovarian cancer.
-
CCT367766
0 ImagesCat. No.: HY-122653CAS No.: 2229856-58-8CCT367766 is a pirin PROTAC degrader. CCT367766 forms a ternary complex with cereblon and induces pirin depletion via the ubiquitin-proteasome pathway in a concentration- and time-dependent manner. CCT367766 can be used for ovarian cancer research.
